Dr. Lohitha Malipeddi, Dr. K Shanmuganadan, Dr. Suresh Kanna


Gout is a metabolic disease, which is characterized by acute or chronic
arthritis, and deposition of monosodium urate crystals in joint, bones,
soft tissues, and kidneys . Gout can either manifest as acute arthritis or
chronic arthropathy, which is also called tophaceous gout.The
prevalence of gout and hyperuricemia is on the rise in developing
countries probably related to population aging,alcohol intake,
hypertension,obesity,metabolic syndrome.

Full Text:



Wernick R, Winkler C,Campbell S:Tophi as initial manifestation of gout Arch intern med 1992,I 52:873.

Urano W,Yamanaka H: The inflammatory process in mechanism of decreased serum uric acid during acute gouty arthritis.J Rheumatol 2002,29(9): 1950-3.

Simkin PA : The pathogenesis of Podagra.Ann intern Med 1977,86:230

Hollingworth P,Scott J T,Burry HC : Non articular gout: hyperuricemia and tophus formation without gouty arthritis.Arthritis Rheum 1983,26:98-101

Beutler A, Schumacher HR Jr: Gout and 'pseudogout': when are arthritic symptoms caused by crystal disposition? Postgrad Med 1994, 95:103-6.

Schumacher HR, Phelps P, Agudelo CA: Urate crystal induced inflammation in dog joints: sequence of synovial changes. J Rheumatol 1974, 1:102.

Gordon TP, Kowanko IC, James M, Roberts-Thomson PJ: Monosodium urate crystal-induced prostaglandin synthesis in the rat subcutaneous air pouch. Clin Exp Rheumatol 1985, 3:291.

Malawista SE, Duff GW, Atkins E, Cheung HS, McCarty DJ: Crystalinduced endogenous pyrogen production. A further look at gouty inflammation. Arthritis Rheum 1985, 28:1039.

Falasca GF, Ramachandrula A, Kelley KA, O'onnor CR, Reginato AJ: Superoxide anion production and phagocytosis of crystals by cultured endothelial cells. Arthritis Rheum 1993, 36:105.

Sutaria S, Katbamna R, Underwood M: Effectiveness of interventions for the treatment of acute and prevention of recurrent gout – a systematic review. Rheumatology (Oxford) 2006, 45:1422.

Wallace SL, Singer JZ: Therapy in gout. Rheum Dis Clin North Am 1988, 14:441.

Janssens HJ, Janssen M, Lisdonk EH van de, van Riel PL, van Weel C: Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. Lancet 371(9627):1854-60. 2008 May 31

Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P, Gerster J, Jacobs J, Leeb B, Lioté F, McCarthy G, Netter P, Nuki G, Perez-Ruiz F, Pignone A, Pimentão J, Punzi L, Roddy E, Uhlig T, Zimmermann-Gòrska I, EULAR Standing Committee for International Clinical Studies Including Therapeutics: EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006, 65(10):1312-24.

So A, De Smedt T, Revaz S, Tschopp J: A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 2007, 9:R28.


  • There are currently no refbacks.